Phase 2 Psoriasis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 70 years (inclusive) with a body mass index (BMI) of 18 or above
• People who have been diagnosed with Psoriatic Arthritis (PsA) for at least 3 months before the screening visit, and who meet a specific set of recognised classification criteria for PsA at screening
• People whose arthritis is currently active, both at the screening visit and at the start of the trial
• People who have previously tried at least one treatment for PsA that either did not work well enough or caused intolerable side effects
• People taking a single conventional disease-modifying medication (a type of drug that slows disease progression) who have been on it for at least 3 months, with the dose unchanged for at least 28 days before the first dose
• People taking anti-inflammatory pain medications (NSAIDs) whose dose has been stable for at least 14 days before the first dose
• People taking oral steroid medications whose dose has been stable for at least 14 days before the first dose
• People using topical (applied to the skin) treatments for plaque psoriasis whose treatment has remained unchanged for at least 14 days before the first dose
• People who are willing and able to attend all required study visits and complete all study procedures
• People who are willing to sign a consent form agreeing to take part
• Women who could become pregnant, and men, who agree to use effective contraception throughout the study and for 6 months after it ends

Who may not be able to join:

• People who have a type of psoriasis other than plaque psoriasis (such as guttate, pustular, or drug-induced psoriasis) at the time of screening or first dose
• People who have another autoimmune condition, such as rheumatoid arthritis or lupus
• People with currently active (symptomatic) fibromyalgia
• People who are pregnant or breastfeeding
• People with a serious or unstable medical condition, or an active localised infection
• People who have had major surgery within 30 days before the first dose, or who have surgery planned during the study
• People who have had cancer or a lymphoproliferative (lymph system) disease within the past 5 years
• People with moderate to severe heart failure, a history of significant heart rhythm problems, or who require ongoing medication to manage heart rhythm
• People with uncontrolled high blood pressure at the time of screening or at the point of being assigned to a treatment group
• People with a history of blood clot-related disease within 24 weeks before screening
• People with a history of a heart attack or major stroke within 24 weeks before screening
• People with a current or recent (within 3 months) digestive system condition that could affect how the study medication is absorbed, including recent gastrointestinal surgery
• People who have had significant blood loss (more than 500 mL) or a blood transfusion within 4 weeks before being assigned to a treatment group
• People who are unable to take medication by mouth
• People who are unable to have blood drawn through a needle in a vein
• People with a history of substance abuse who are unable to abstain, or who have a psychiatric condition
• People with active tuberculosis identified on a chest X-ray taken within 6 months before screening (confirm with trial site for specific X-ray timing requirements)
• People with hepatitis B, hepatitis C, HIV, or syphilis requiring treatment
• People with significant abnormalities found during physical examination or blood/laboratory tests
• People with a history of a major drug allergy, or a known allergy to any ingredient in the study medication
• People who have taken part in another clinical trial or used another investigational drug (other than for psoriatic arthritis) within 4 weeks before the first dose
• People who have had, or are planning, a bone marrow transplant or solid organ transplant
• People who have previously used certain biologic medications (specific details apply per the trial protocol — confirm with trial site)
• People whose situation, in the trial doctor's judgement, poses a serious safety risk or would prevent them from completing the study

Important: Always verify eligibility with the trial site directly before applying.